Through direct modification, researchers have also created many exosomes with specific targeting properties, such as EV coupling with EGFR‐targeted peptides or anti‐EGFR nano‐antibodies to promote their accumulation in EGFR‐positive cancer cells, which can enable PTX delivery to significantly enhance drug efficacy in EGFR‐positive lung cancer.319. This evidence concerns the gene EGFR and lung cancer.